Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

PHASE1CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

August 4, 2010

Primary Completion Date

December 12, 2016

Study Completion Date

December 12, 2016

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

MART-1

THIS PEPTIDE REMOVED FROM STUDY ON 1/1/2013. MART-1:26-35(27L) peptide vaccine

BIOLOGICAL

NY-ESO-1

NY-ESO-1 peptide vaccine

BIOLOGICAL

gp100:209-217(210M)

THIS PEPTIDE REMOVED FROM STUDY ON 1/1/2013. gp100:209-217(210M) peptide vaccine

BIOLOGICAL

gp100:280-288(288V)

gp100:280-288(288V) peptide vaccine

DRUG

Montanide ISA 51 VG

Administer peptide vaccine emulsions prepared with Montanide® ISA 51 VG by deep subcutaneous injection.

BIOLOGICAL

BMS-936558

BMS-936558 is a fully human monoclonal antibody (HuMAb) against programmed death-1 (PD-1). Level 1: 1 mg/kg cohort; Level 2: 3 mg/kg cohort; Level 3: 10 mg/kg cohort; Level 4: 3 mg/kg prior ipi gr 0/1/2 cohort; Level 5: 3 mg/kg prior ipi gr 3 cohort; Level 6: 3 mg/kg BMS-936558 (no peptide vaccine; human leukocyte antigen \[HLA\] unrestricted)

Trial Locations (1)

33612-9497

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Medarex

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT01176461 - Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558 | Biotech Hunter | Biotech Hunter